Annual incidence rates of herpes zoster among an immunocompetent population in the United States

Annual incidence rates of herpes zoster among an immunocompetent population in the United States

Deconditioning is also known as aggressive systemic infantile myofibromatosis, amyotrophy, amyotrophy due to herpes zoster, atrophic myositis, atrophy of muscle due to disuse, atrophy of muscle, idiopathic, benign monomelic amyotrophy, congenital fibrosis of inferior rectus muscle, congenital fibrosis syndrome, denervation atrophy of muscle, disuse muscle atrophy, idiopathic muscle atrophy, ischemic muscular atrophy, leg wasted, muscle atrophy, muscle atrophy of ankle and foot, muscle atrophy of ankle and/or foot, muscle atrophy of forearm, muscle atrophy of hand, muscle atrophy of L ankle and foot, muscle atrophy of L forearm, muscle atrophy of L hand, muscle atrophy of L lower leg, muscle atrophy of L shoulder, muscle atrophy of L thigh, muscle atrophy of L upper arm, muscle atrophy of left ankle and foot, muscle atrophy of left ankle and/or foot, muscle atrophy of left forearm, muscle atrophy of left hand, muscle atrophy of left lower leg, muscle atrophy of left shoulder, muscle atrophy of left thigh, muscle atrophy of left upper arm, muscle atrophy of lower leg, muscle atrophy of multiple sites, muscle atrophy of R ankle and foot, muscle atrophy of R forearm, muscle atrophy of R hand, muscle atrophy of R lower leg, muscle atrophy of R shoulder, muscle atrophy of R thigh, muscle atrophy of R upper arm, muscle atrophy of right ankle and foot, muscle atrophy of right ankle and/or foot, muscle atrophy of right forearm, muscle atrophy of right hand, muscle atrophy of right lower leg, muscle atrophy of right shoulder, muscle atrophy of right thigh, muscle atrophy of right upper arm, muscle atrophy of shoulder, muscle atrophy of thigh, muscle atrophy of upper arm, muscular atrophy ataxia retinitis pigmentosa, and diabetes mellitus, myofibrosis, on examination – muscle atrophy present, on examination – quadriceps muscle wasting, parasitic myositis, severe systemic illness respiratory muscle fatigue, and severe systemic illness-induced respiratory muscle wasting. Most cases are in children under age 15, but older children and adults can get it. Dentin hypersensitivity – wikipedia, free encyclopedia, Dentin hypersensitivity (abbreviated to dh, or dhs, and also termed sensitive dentin, dentin sensitivity, cervical sensitivity, and cervical hypersensitivity) is. Can’t find a code? Immunocompetent adult patients, enrolled as of January 1, 2011 were analyzed. The denominator was defined as eligible subjects who were immunocompetent, had no evidence of zoster vaccination, and no diagnosis of HZ (International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis code 053.xx) in the 90 days prior to January 1, 2011. Do not use aspirin for chickenpox; that combination can cause Reye syndrome.

| Read SourcesDr gily’ icd-9-cm icd-10-cm , Icd-9 code description icd-10 code(s) description 053.20 herpes zoster dermatitis of eyelid b02.39 other herpes zoster eye disease.Icd – 9 code diagnosis – aaomp, Icd-9 code diagnosis 521.2 abrasion 526.4 abscess, bone look up code abscess, by location (procedure code 88304) 522.7 abscess, periapical, with fistula. Annual IRs were calculated for the entire population in the database as well as by gender and age group; standardized IRs were also produced using the 2010 US Census data. The overall annual IR of HZ across all ages was 4.47 per 1000 person-years (95 % confidence interval [CI]: 4.44–4.50) which monotonically increased with age from 0.86 (95 % CI: 0.84–0.88) for those aged ≤19 to 12.78 (95 % CI: 12.49–13.07) for patients ≥80 years. The IR was 8.46 (95 % CI: 8.39–8.52) among adults ≥50 years and 10.46 (95 % CI: 10.35–10.56) among those aged ≥60 years. You probably will not get chickenpox again, but the virus can cause shingles in adults. 3.66, 95 % CI: 3.62–3.69) and this was seen across all age groups. When adjusted for age and gender using 2010 US Census data, the annual IR was 4.63 per 1000 person-years (95 % CI: 4.61–4.66).

Annual incidence rates of herpes zoster among an immunocompetent population in the United States
Despite the availability of a vaccine, HZ remains common among immunocompetent adults in the US with incidence rates of HZ observed to increase with age and be higher in women than men. Herpes zoster (HZ), or shingles, is caused by reactivation of the varicella zoster virus (VZV) and mainly affects the elderly population [1–3]. In the United States, over 99 % of adults have serological evidence of VZV infection and are susceptible to HZ [4], and the individual lifetime risk of HZ is approximately 30 % [5]. It is estimated that approximately 1 million new cases of HZ are diagnosed each year. While susceptibility to HZ increases with advancing age, the rate of incidence significantly increases among patients aged >50 years, with a drastic rise in the rate thereafter [2, 6]. The incidence rate of HZ ranged between three and five per 1,000 person-years from prior studies in the US and other countries, depending on the population studied and immunocompetency of subjects [5, 7–10]. However, estimates are prior to the introduction of a zoster vaccine in the United States.

Zostavax®, a live attenuated zoster vaccine approved in the US for the prevention of HZ in immunocompetent adults 50 years of age and older, is recommended by the US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) for use among immunocompetent adults aged 60 years and older [11]. In a large randomized clinical trial, zoster vaccine was shown to reduce the incidence of HZ by 51.3 % and the incidence of postherpetic neuralgia (PHN) by 66.5 %, in immunocompetent adults 60 years of age and older [6]. In addition, the Zostavax Efficacy and Safety Trial (ZEST) demonstrated that zoster vaccine reduced the risk of HZ in adults 50 to 59 [12]. The economic value of the zoster vaccine has been reviewed and synthesized elsewhere [13]. In spite of vaccine availability, HZ continues to pose a significant burden in the US. Despite ACIP recommendations, in 2011 only 15.8 % of adults aged ≥60 years reported ever receiving the zoster vaccine [14]. Previous studies found that the incidence rate of HZ has changed over time, and updated data on age-specific and sex-specific incidence rates using a nationwide database is important to understand the population at risk of HZ.

The objective of the current study is to estimate the overall and age- and sex-specific incidence rates of HZ among immunocompetent US adults in 2011 following availability of a vaccine. This retrospective, observational cohort study was conducted using administrative claims data from two Truven Health MarketScan® Research Databases – the Commercial Claims and Encounters and the Medicare Supplemental and Coordination of Benefits—for the period January 1, 2011 through December 31, 2011. Both databases include complete longitudinal records of inpatient services, outpatient services, long-term care, and prescription drug claims covered under a variety of fee-for-service and managed care health plans, including exclusive provider organizations, preferred provider organizations, point of service plans, indemnity plans, and health maintenance organizations. The MarketScan Research database records are de-identified and compliant with US patient confidentiality requirements, including the Health Insurance Portability and Accountability Act 1996. Permissions were not needed to utilize these data. Since this study used only de-identified patient records and did not involve the collection, use, or transmittal of individually identifiable data, Institutional Review Board approval was not necessary. Patients with and without HZ (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] diagnosis code 053.xx), enrolled as of January 1, 2011, having no claims for HZ or evidence of receiving shingles vaccination in the 90 days prior to January 1, 2011, and meeting criteria for immunocompetent status were included.

A series of selected ICD-9-CM diagnoses, procedures and treatment criteria, informed by the Centers for Disease Control and Prevention [11] were used to determine the immunocompetent status of each patient. Patients were excluded if they had ICD-9-CM diagnosis or procedure codes for hematologic malignancy, solid tumor malignancy, human immunodeficiency virus, chronic renal failure, nephrotic syndrome, and other select immunocompromising conditions. Patients were also excluded if they had evidence of organ transplantation, procedures indicating injection or infusion of cancer chemotherapeutic substance, immunotherapy as antineoplastic agent, poisoning by antineoplastic and immunosuppressive drugs, or treatment with chemotherapy, radiation therapy, corticosteroids, tumor necrosis factor inhibitors, protease inhibitors, reverse transcriptase inhibitors, azathioprine, cyclosporine, or tacrolimus.

You may also like